SCHEMBL16832385

SCHEMBL16832385

Cc1nn(Cc2ccc(F)cc2)c(C)c1NC(=O)c1cc(C(N)=O)c2ccccc2n1

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 14/20 0.70
SLC2A3 P11169 13/20 0.64
SLC2A4 P14672 13/20 0.64
SLC2A2 P11168 6/20 0.61
TP53 P04637 2/20 0.58
KMT2A Q03164 2/20 0.55
KDM4E B2RXH2 1/20 0.55
ADORA3 P0DMS8 1/20 0.54
HRH2 P25021 1/20 0.54
HRH1 P35367 1/20 0.54
PTGER4 P35408 1/20 0.54
MEN1 O00255 1/20 0.54
ALDH1A1 P00352 1/20 0.54
POLB P06746 1/20 0.54
BRCA1 P38398 1/20 0.54
RECQL P46063 1/20 0.54
HSD17B10 Q99714 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16855671 0.94 SLC2A1 (0.75) SLC2A1SLC2A3SLC2A4SLC2A2TP53
SCHEMBL16833143 0.92 SLC2A1 (0.60) SLC2A1SLC2A3SLC2A4SLC2A2TP53
SCHEMBL16832462 0.90 SLC2A1 (0.73) SLC2A1SLC2A3SLC2A4SLC2A2ADORA3
SCHEMBL16833024 0.90 SLC2A1 (0.58) SLC2A1SLC2A3SLC2A4SLC2A2TP53
SCHEMBL16855553 0.90 SLC2A1 (0.75) SLC2A1SLC2A3SLC2A4SLC2A2TP53
SCHEMBL16833585 0.90 SLC2A1 (0.57) SLC2A1SLC2A3SLC2A4SLC2A2ALDH1A1
SCHEMBL16834152 0.90 SLC2A1 (0.75) SLC2A1SLC2A3SLC2A4SLC2A2TP53
SCHEMBL16834032 0.90 SLC2A1 (0.63) SLC2A1SLC2A3SLC2A4SLC2A2ADORA3
SCHEMBL16833271 0.89 SLC2A1 (0.57) SLC2A1SLC2A3SLC2A4SLC2A2TP53
SCHEMBL16833098 0.89 SLC2A1 (0.60) SLC2A1SLC2A3SLC2A4SLC2A2ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170037028-A1 GLUCOSE TRANSPORT INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-02-09 US claimed
EP-3083598-A1 GLUCOSE TRANSPORT INHIBITORS Bayer Pharma Aktiengesellschaft (DE) 2016-10-26 EP claimed
WO-2015091428-A1 GLUCOSE TRANSPORT INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-06-25 WO claimed
US-20170037028-A1 GLUCOSE TRANSPORT INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-02-09 US disclosed
EP-3083598-A1 GLUCOSE TRANSPORT INHIBITORS Bayer Pharma Aktiengesellschaft (DE) 2016-10-26 EP disclosed
WO-2015091428-A1 GLUCOSE TRANSPORT INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170037028-A1 GLUCOSE TRANSPORT INHIBITORS SLC2A1, SLC2A2, SLC2A4 SLC2A1 1/4885SLC2A3 4/4885SLC2A4 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.